Top

Published in:

01-04-2010 | Original Article

Increased Oxidative Stress, Decreased Total Antioxidant Capacity, and Iron Overload in Untreated Patients with Chronic Hepatitis C

Authors: Danielle Venturini, Andréa Name Colado Simão, Décio Sabbatini Barbosa, Edson Lopes Lavado, Victor Emanuel Soares Narciso, Isaias Dichi, Jane Bandeira Dichi

Published in: Digestive Diseases and Sciences | Issue 4/2010

Abstract

The aim of this study was to determine oxidative stress in patients with untreated chronic hepatitis C (CHC), relating the obtained results with iron status and disease activity markers. Two groups (CHC patients and controls) were studied. CHC patients presented significantly higher values than the control group in some parameters: ALT, AST, GGT, iron, ferritin, and transferrin saturation, and also in tert-butyl hydroperoxide initiate chemiluminescence and thiobarbituric acid-reactive substances (TBARS) as well as lower values in total radical-trapping antioxidant parameter (TRAP). TBARS showed a significant correlation with serum AST and with transferrin saturation, whereas TRAP correlated inversely with serum albumin. Serum ferritin correlated with ALT and GGT, whereas serum iron did so with GGT. In conclusion, lower antioxidant capacity, higher levels of pro-oxidants activity, and iron overload occur in untreated patients with CHC. This greater oxidative activity could play an important role in pathogenesis and evolution of hepatitis C and thus further investigations.

Lauer G, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. doi:10.1056/NEJM200107053450107.CrossRefPubMed

De Maria N, Colantoni A, Fagiuoli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med. 1996;21:291–295. doi:10.1016/0891-5849(96)00044-5.CrossRefPubMed

Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res. 2006;34:65–73. doi:10.1016/j.hepres.2005.11.001.CrossRefPubMed

Levent G, Ali A, Ahmet A, et al. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med. 2006;4:25–30. doi:10.1186/1479-5876-4-25.CrossRefPubMed

Reiss CS, Komatzu T. Does nitric oxide play a critical role in viral infections? J Virol. 1998;72:4547–4551.PubMed

Curran RD, Billiar TR, Stuehr DJ, et al. Multiples cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann Surg. 1990;212:462–469. doi:10.1097/00000658-199010000-00009.CrossRefPubMed

Geller DA, DiSilvio M, Nussler AK, et al. Nitric oxide synthase expression is induced in hepatocytes in vivo during hepatic inflammation. J Surg Res. 1993;55:427–432. doi:10.1006/jsre.1993.1164.CrossRefPubMed

Kandemir Ö, Polat A, Kaya A. Inducible nitric oxide synthase expression in chronic viral hepatitis and its relation with histological severity of disease. J Viral Hepat. 2002;9:419–423. doi:10.1046/j.1365-2893.2002.00382.x.CrossRefPubMed

Arber N, Konikoff FM, Moshkowitz M, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci. 1994;39:2656–2659. doi:10.1007/BF02087705.CrossRefPubMed

10.

Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology. 2000;32:135–138. doi:10.1053/jhep.2000.8700.CrossRefPubMed

11.

Iwasa M, Iwata K, Kaito M, et al. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C. Nutrition. 2004;20:368–371. doi:10.1016/j.nut.2003.12.009.CrossRefPubMed

12.

Kugelman A, Choy HA, Liu R, Shi MM, Gozal E, Forman HJ. Gamma-glutamyl transpeptidase is increased by oxidative stress in rat alveolar L2 epithelial cells. Am J Respir Cell Mol Biol. 1994;11:586–592.PubMed

13.

Lee DH, Blomhoff R Jr, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535–539. doi:10.1080/10715760410001694026.CrossRefPubMed

14.

Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol. 2002;36:805–811. doi:10.1016/S0168-8278(02)00060-0.CrossRefPubMed

15.

Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress n patients with chronic hepatitis C. Am J Gastroenterol. 2002;97:2634–2639. doi:10.1111/j.1572-0241.2002.06041.x.CrossRefPubMed

16.

Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med. 2000;29:1106–1114. doi:10.1016/S0891-5849(00)00394-4.CrossRefPubMed

17.

Repetto M, Reides C, Carretero MLG, Costa M, Griembertg G, Llesuy S. Oxidative stress in blood of HIV infected patients. Clin Chim Acta. 1996;255:107–117. doi:10.1016/0009-8981(96)06394-2.CrossRefPubMed

18.

Flecha BG, Llesuy S, Boveris A. Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, Liver, and muscle. Free Radic Biol Med. 1991;10:93–100. doi:10.1016/0891-5849(91)90002-K.CrossRef

19.

Jentzsch AM, Bachmann H, Fürst P, Biesalski HK. Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med. 1996;20:251–256. doi:10.1016/0891-5849(95)02043-8.CrossRefPubMed

20.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thibarbituric acid reaction. Anal Biochem. 1979;95:351–358. doi:10.1016/0003-2697(79)90738-3.CrossRefPubMed

21.

Guevara I, Iwanejko J, Dembinska-Kiéc A, et al. Determination of nitrito/nitrate in human biological material by the simple Griess reaction. Clin Chim Acta. 1998;274:177–188. doi:10.1016/S0009-8981(98)00060-6.CrossRefPubMed

22.

Parola M, Robino G. Oxidative stress related molecules and liver fibrosis. J Hepatol. 2001;35:297–306. doi:10.1016/S0168-8278(01)00142-8.CrossRefPubMed

23.

Cecchini R, Aruoma OI, Halliwell B. The action of hydrogen peroxide on the formation of thiobarbituric acid-reactive material from microsomes or from DNA damage by bleomycin or o-phenanthroline. Artefacts in the thiobarbituric acid test. Free Radic Res Commun. 1990;10:245–258. doi:10.3109/10715769009149893.CrossRefPubMed

24.

Casado MF, Cecchini AL, Simão ANC, Oliveira RD, Cecchini R. Free radical-mediated pre-hemolytic injury in human red blood cells subjected to lead acetate as evaluated by chemiluminescence. Food Chem Toxicol. 2007;45:945–952. doi:10.1016/j.fct.2006.12.001.CrossRefPubMed

25.

Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001;61:8697–8702.PubMed

26.

Basset SE, Di Bisceglie AM, Bacon BR, et al. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology. 1999;29:1884–1892. doi:10.1002/hep.510290623.CrossRef

27.

National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–94. Center for Disease Control and prevention, 1996. http://www.healthyarkansas.com/services/C_training/edu/glossary/defalt.htm.

28.

Kawamura Y, Akuta N, Sezaki H, et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol. 2005;40:901–906. doi:10.1007/s00535-005-1636-6.CrossRefPubMed

29.

Alexander J, Tung BY, Croghan A, Kowdley KV. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver Int. 2007;27:268–273. doi:10.1111/j.1478-3231.2007.01449.x.CrossRefPubMed

30.

Radisky DC, Kaplan J. Iron in cytosolic ferritin can be recycled through lysossomal degradation in human fibroblasts. Biochem J. 1998;336:201–205.PubMed

31.

Kakholon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med. 2002;33:1037–1046. doi:10.1016/S0891-5849(02)01006-7.CrossRef

32.

Tavil AS. Diagnosis and management of hemochromatosis. Hepatology. 2001;33:1321–1328. doi:10.1053/jhep.2001.24783.CrossRef

33.

Simão ANC, Dichi JB, Barbosa DS, Cecchini R, Dichi I. Influence of uric acid and γ -glutamyltransferase on total antioxidant capacity and oxidative stress in patients with metabolic syndrome. Nutrition. 2008;24:675–681. doi:10.1016/j.nut.2008.03.021.CrossRefPubMed

34.

Zhang H, Liu H, Iies KE, et al. 4-Hydroxynonenal induces rat γ-glutamyl transpeptidase through mitogen-activeted protein kinase-mediated electrophile response element/nuclear factor erythroyd 2–related factor 2 signaling. Am J Respir Cell Mol Biol. 2006;34:174–181. doi:10.1165/rcmb.2005-0280OC.CrossRefPubMed

35.

Stark AA, Russel JJ, Langenbach R, Pagano DA, Zeiger E, Huberman E. Localization of oxidative damage by glutathione-gamma-glutamyl transpeptidase system in preneoplasic lesions in sections of liver from carcinogen-treated rats. Carcinogenesis. 1994;15:343–348. doi:10.1093/carcin/15.2.343.CrossRefPubMed

36.

Drozdz R, Parmentier C, Hachad H, Leroy P, Siest G, Wellman M. Gamma-glutamyl transferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Free Radic Biol Med. 1998;25:786–792. doi:10.1016/S0891-5849(98)00127-0.CrossRefPubMed

37.

Majano PL, Garcia-Monzon C, Lopez-Cabrera M, et al. Inducible nitric oxide synthase expression in chronic viral hepatitis. J Clin Invest. 1998;101:1343–1352. doi:10.1172/JCI774.CrossRefPubMed

38.

Amaro MJ, Bartolome J, Pardo M, Cotonat T, Lopez-Farre A, Carreno V. Decreased nitric oxide production in chronic viral hepatitis B and C. J Med Virol. 1997;51:326–331. doi:10.1002/(SICI)1096-9071(199704)51:4<326::AID-JMV11>3.0.CO;2-G.CrossRefPubMed

39.

Hokari A, Zeniya M, Hiroyasu E, Ishikawa T, Kurasima Y, Toda G. Role of nitric oxide(NO) in interferon-alpha therapy for hepatitis C. J Infect. 2005;51:47–53. doi:10.1016/j.jinf.2004.08.025.CrossRefPubMed

40.

Tankurt E, Kirkali G, Ozcan MA, Mersin N, Ellidokuz E, Akpinar HA. Increased serum nitrite and nitrate concentrations in chronic hepatitis. J Hepatol. 1998;29:543–544. doi:10.1016/S0168-8278(98)80077-9.CrossRef

41.

Garcia-Monzón C, Majano PL, Zubia I, Sanz P, Apolinario A, Monero-Otero R. Intrahepatic accumulation of nitrotyrosine in chronic viral hepatitis is associated with histological severity of liver disease. J Hepatol. 2000;32:331–338. doi:10.1016/S0168-8278(00)80080-X.CrossRefPubMed

42.

Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. Mol Med. 2000;6:347–373.PubMed

43.

Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–6862. doi:10.1073/pnas.78.11.6858.CrossRefPubMed

44.

Mayer M. Association of serum bilirrubin concentration with risk of coronary artery disease. Clin Chem. 2000;46:1723–1727.PubMed

Title: Increased Oxidative Stress, Decreased Total Antioxidant Capacity, and Iron Overload in Untreated Patients with Chronic Hepatitis C
Authors: Danielle Venturini
Andréa Name Colado Simão
Décio Sabbatini Barbosa
Edson Lopes Lavado
Victor Emanuel Soares Narciso
Isaias Dichi
Jane Bandeira Dichi
Publication date: 01-04-2010
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 4/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-009-0833-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Melatonin Modulates the Severity of Taurocholate-Induced Acute Pancreatitis in the Rat

Acute Hepatitis Due to Epstein–Barr Virus in an Immunocompetent Patient

Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation

Determinants of Accelerated Small Intestinal Transit in Alcohol-Related Chronic Pancreatitis

Liver Transplantation in the Ethnic Minority Population: Challenges and Prospects

Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials